These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6378807)

  • 21. [A multicenter clinical comparison study between Tevacor and Trasicor in hypertension].
    Shmueli H; Rosenfeld J
    Harefuah; 1986 Jun; 110(11):550-2. PubMed ID: 3533738
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone.
    Nissinen A; Tuomilehto J
    Pharmatherapeutica; 1980; 2(7):462-8. PubMed ID: 7010382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisoprolol vs. chlorthalidone: a randomized, double-blind, comparative study in arterial hypertension.
    Bueno J; Amiguet JA; Carasusan J; Cebollada J; Carretero J
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S189-92. PubMed ID: 11527126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An example of an acceptable combination in the treatment of arterial hypertension].
    Menard J; Plouin PF; Gouin F; Corvol P; Milliez P
    Sem Hop; 1978 Feb; 54(4):201-6. PubMed ID: 208167
    [No Abstract]   [Full Text] [Related]  

  • 26. [Report on the clinical evaluation of the antihypertensive effects of Urandil A VUFB].
    Suchová H; Mayer O; Cepelák V
    Vnitr Lek; 1984 Feb; 30(2):169-74. PubMed ID: 6372237
    [No Abstract]   [Full Text] [Related]  

  • 27. [Long-term experiences with an antihypertensive combination].
    Hilgert A; Horch G
    Med Welt; 1982 Jul; 33(29-30):1067-70. PubMed ID: 6750310
    [No Abstract]   [Full Text] [Related]  

  • 28. Atenolol and chlorthalidone administered alone and in combination for essential hypertension.
    Boike SC; Durley Y; Cubberley RB
    Clin Pharm; 1982; 1(5):449-53. PubMed ID: 6764166
    [No Abstract]   [Full Text] [Related]  

  • 29. [A double blind trial : oxprenolol/diazepam (author's transl)].
    Scharbach H
    Encephale; 1981; 7(1):51-8. PubMed ID: 7014193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antihypertensive effect and adverse effects of treatment with beta-blocking agents].
    Andersson O; Berglund G; Bergman H; Cramér K; Fagerberg SE; Forsberg SA; Johnsen V; Lundkvist L; Rutle O; Sjolyst R
    Lakartidningen; 1975 Nov; 72(48):4738-40. PubMed ID: 1105030
    [No Abstract]   [Full Text] [Related]  

  • 31. Once daily combination therapy for hypertension.
    Asbury MJ; Wells FO; Barker NP
    Practitioner; 1980 Dec; 224(1350):1306-9. PubMed ID: 7012818
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of moderate salt restriction in hypertensive patients treated with oxprenolol or chlorthalidone.
    Pollavini G; Comi D; Grillo C; Lombardo M; Mantero O; Minetti L; Selvini A; Suppa G
    Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):451-5. PubMed ID: 6490228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experience in the ambulatory treatment of primary arterial hypertension with a fixed oxprenolol-chlorthalidone combination].
    Zampaglione G; Ferrari O; Bianchi C; Bonifazi C; Coppetti S; Costanza G; Lanzarini L; Ricevuti A; Rinaldo R; Rizzi GM; Tavecchi L; Ziletti G; Distante S
    G Clin Med; 1980 Oct; 61(10):776-88. PubMed ID: 7239053
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparative study of the hypotensive effect of a combination of oxprenolol-chlortalidone with single and fractionated administration].
    Rubegni M; Provvedi D; Bandinelli C; Bellini PG; De Mauro G
    Boll Soc Ital Cardiol; 1976; 21(10):1853-8. PubMed ID: 1031614
    [No Abstract]   [Full Text] [Related]  

  • 35. One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension.
    Masoni A; Tomasi AM; Pirani R; Lazzaretto R; Ambroso G
    G Ital Cardiol; 1981; 11(12):2105-9. PubMed ID: 7346306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
    Applegate WB; Pressel S; Wittes J; Luhr J; Shekelle RB; Camel GH; Greenlick MR; Hadley E; Moye L; Perry HM
    Arch Intern Med; 1994 Oct; 154(19):2154-60. PubMed ID: 7944835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
    Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.